Trial Profile
A Phase 1 Open-Label, Dose Escalation Study of OTX-TKI for Intravitreal Use in Subjects With Neovascular Age-Related Macular Degeneration (AMD)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 23 Sep 2022
Price :
$35
*
At a glance
- Drugs Axitinib (Primary) ; Aflibercept; Bevacizumab; Ranibizumab
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors Ocular Therapeutix
- 22 Sep 2022 According to an Ocular Therapeutix media release, data from this trial will be presented at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting.
- 02 Aug 2022 Status changed from recruiting to active, no longer recruiting.
- 28 Feb 2022 According to an Ocular Therapeutix media release, interim data presented at the Angiogenesis, Exudation, and Degeneration 2022 Meeting.